Dr. Falchook on KTN3379 in Advanced Tumors

Gerald S. Falchook, MD
Published: Friday, Jul 29, 2016


Gerald S. Falchook, MD, director, Drug Development, Sarah Cannon Research Institute, discusses a phase Ib study examining the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of the anti-ERBB3 agent KTN3379 in adults with advanced tumors. The agent was studied alone and with targeted therapies.

The targeted agents that KTN3379 was combined with in this study included trastuzumab (Herceptin), cetuximab (Erbitux), erlotinib (Tarceva), and vemurafenib (Zelboraf). Each of the agents in these combinations were administered at full doses, Falchook explains.

KTN3379 is a monoclonal antibody designed to target receptors of EGFR, HER2, ERBB3, and ERBB4. It binds to a unique epitope with high affinity, which is associated with a longer half-life and slower clearance compared with other agents in its class. These characteristics can help engage the target for a longer amount of time, Falchook says.

Gerald S. Falchook, MD, director, Drug Development, Sarah Cannon Research Institute, discusses a phase Ib study examining the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of the anti-ERBB3 agent KTN3379 in adults with advanced tumors. The agent was studied alone and with targeted therapies.

The targeted agents that KTN3379 was combined with in this study included trastuzumab (Herceptin), cetuximab (Erbitux), erlotinib (Tarceva), and vemurafenib (Zelboraf). Each of the agents in these combinations were administered at full doses, Falchook explains.

KTN3379 is a monoclonal antibody designed to target receptors of EGFR, HER2, ERBB3, and ERBB4. It binds to a unique epitope with high affinity, which is associated with a longer half-life and slower clearance compared with other agents in its class. These characteristics can help engage the target for a longer amount of time, Falchook says.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x